We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Horizon (HZNP) Submits sBLA for Krystexxa Label Expansion
Read MoreHide Full Article
Horizon Therapeutics plc announced that it has submitted a supplemental biologics license application (sBLA) to the FDA for the label expansion of its marketed drug, Krystexxa. The sBLA is seeking approval of Krystexxa plus methotrexate for the treatment of people living with uncontrolled gout.
The regulatory body is expected to complete its review during the second half of 2022.
The sBLA was based on data from the MIRROR randomized clinical study, which evaluated Krystexxa plus methotrexate in patients with uncontrolled gout. In October 2021, Horizon announced positive top-line data from the above study that showed that 71% of patients who received treatment with Krystexxa plus methotrexate achieved a complete serum uric acid (sUA) response, which is defined as sUA<6 mg/dL at least 80% of the time during month six.
Krystexxa is currently approved for the treatment of adult patients with chronic gout refractory to conventional therapies, also called uncontrolled gout.
Per the press release, the above-mentioned sBLA seeks to update the prescribing information to include Krystexxa plus methotrexate, an immunomodulator often used to improve response rates.
Shares of Horizon have rallied 20.5% in the past year against the industry’s decline of 31.3%.
Image Source: Zacks Investment Research
Horizon’s portfolio of marketed drugs, including Krystexxa, has been witnessing a solid uptake. The company reports financial results under two segments, namely Orphan (previously known as the Orphan and Rheumatology segment) and Inflammation (previously known as the primary care segment).
Sales in the Orphan segment are being driven by the strong uptake of Tepezza as well as the continued growth of Krystexxa, Ravicti, Procysbi and Actimmune.
In the first nine months of 2021, Krystexxa generated sales worth $395.2 million, reflecting an increase of 42.7% year over year. A potential label expansion of the drug will make it eligible to serve a broader patient population and boost sales further in the days ahead.
However, competition remains stiff for Horizon in the target market as other companies are developing their candidates for the treatment of gout. Selecta Biosciences, Inc. is evaluating its pipeline candidate in a late-stage study for the treatment of chronic refractory gout.
Selecta Biosciences has completed enrollment in the phase III DISSOLVE I study, which is evaluating SEL-212 for treating chronic refractory gout. Top-line data from the same is expected in the second half of 2022.
Image: Bigstock
Horizon (HZNP) Submits sBLA for Krystexxa Label Expansion
Horizon Therapeutics plc announced that it has submitted a supplemental biologics license application (sBLA) to the FDA for the label expansion of its marketed drug, Krystexxa. The sBLA is seeking approval of Krystexxa plus methotrexate for the treatment of people living with uncontrolled gout.
The regulatory body is expected to complete its review during the second half of 2022.
The sBLA was based on data from the MIRROR randomized clinical study, which evaluated Krystexxa plus methotrexate in patients with uncontrolled gout. In October 2021, Horizon announced positive top-line data from the above study that showed that 71% of patients who received treatment with Krystexxa plus methotrexate achieved a complete serum uric acid (sUA) response, which is defined as sUA<6 mg/dL at least 80% of the time during month six.
Krystexxa is currently approved for the treatment of adult patients with chronic gout refractory to conventional therapies, also called uncontrolled gout.
Per the press release, the above-mentioned sBLA seeks to update the prescribing information to include Krystexxa plus methotrexate, an immunomodulator often used to improve response rates.
Shares of Horizon have rallied 20.5% in the past year against the industry’s decline of 31.3%.
Horizon’s portfolio of marketed drugs, including Krystexxa, has been witnessing a solid uptake. The company reports financial results under two segments, namely Orphan (previously known as the Orphan and Rheumatology segment) and Inflammation (previously known as the primary care segment).
Sales in the Orphan segment are being driven by the strong uptake of Tepezza as well as the continued growth of Krystexxa, Ravicti, Procysbi and Actimmune.
In the first nine months of 2021, Krystexxa generated sales worth $395.2 million, reflecting an increase of 42.7% year over year. A potential label expansion of the drug will make it eligible to serve a broader patient population and boost sales further in the days ahead.
However, competition remains stiff for Horizon in the target market as other companies are developing their candidates for the treatment of gout. Selecta Biosciences, Inc. is evaluating its pipeline candidate in a late-stage study for the treatment of chronic refractory gout.
Selecta Biosciences has completed enrollment in the phase III DISSOLVE I study, which is evaluating SEL-212 for treating chronic refractory gout. Top-line data from the same is expected in the second half of 2022.
Zacks Rank & Stocks to Consider
Horizon currently carries a Zacks Rank #3 (Hold). Top-ranked stocks in the biotech sector include Precision BioSciences, Inc. (DTIL - Free Report) and AnaptysBio, Inc. (ANAB - Free Report) , both sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Precision BioSciences’ loss per share estimates have narrowed 20.1% for 2022, over the past 60 days.
Precision BioSciences’ earnings surpassed estimates in each of the trailing four quarters.
AnaptysBio’s loss per share estimates have narrowed 0.3% for 2022, over the past 60 days. The stock has rallied 39.4% in the past year.
AnaptysBio’s earnings surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.